PDCD1 and non-small cell lung carcinoma: In 2020, a clinical study reported the use of PD-1 knockout T cells to treat patients with NSCLC that was refractory to radiotherapy and chemotherapy;357 it demonstrated that CRISPR engineering is safe in T cells, which paves the way for combining CRISPR technology with other T-cell modification approaches.